MYC and breast carcinoma: The characteristics of our Myc;Ptenfl model provide insight into the molecular pathways involved in specific breast cancer subtypes and should serve as a platform for preclinical drug screening of heterogeneous TNBC with metastasis, including both cell-intrinsic targeted therapy strategies and the testing of immunotherapies, and combinations thereof.